KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, announced the launch of SUREmAb. The product builds on the power of KBI’s SUREtechnology Platform™ to enable optimized, safe and cost-effective monoclonal antibody (mAb) development and production.
SUREmAb is a vertically integrated global solution designed to minimize development time for biopharmaceutical manufacturers worldwide. The solution enables research cell bank (RCB) development in as little as nine weeks and enables customers to go from DNA to GMP medicine in as little as 11 months. In addition, SUREmAb is designed with titers up to 10 g/L and associated lower operating process costs, thereby improving operational efficiency and maximizing return on investment.
“SUREmAb is not only the culmination of decades of biologics manufacturing expertise, but also our vision for the future of mAb development,” said Sigma Mostafa, Chief Scientific Officer at KBI. “We are proud to launch such a platform in an era where time, efficiency and innovation intersect. . Not only does it speed up the development process, but it is also high quality and cost-effective from the start. At KBI, we believe in our ability to anticipate market changes and come up with pioneering solutions that address future challenges, SUREmAb This is clear evidence of that commitment.”
Also Read : GenScript Biotech Corporation Presents the 3rd Annual Gene and Cell Engineering Summit
KBI Biopharma and Selexis announced a business integration during the 2023 North American Biotechnology Industry Exhibition (BIO International 2023), which played an important role in the operation of SUREmAb technology, allowing KBI to streamline processes and improve the efficiency of monoclonal antibody development and production. The solution builds on more than 15 years of leadership in mAb development and strengthens KBI’s industry expertise and position in global markets. The company has developed more than 150 unique therapeutic mAb programs and seven commercial mAb programs using the SUREtechnology Platform.
JD Mowery, CEO of KBI, said: “We recognize the need to be a strong partner to our customers with novel therapies so they have the best chance of benefiting as many patients as possible. Simplified access to SUREmAbs and continued KBI production demonstrate that, We are committed to supporting industry development by removing key barriers to research and development.”
SUREmAb meets global regulatory compliance standards, ensuring a simple and clear experience when targeting markets regulated by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
SOURCE: Businesswire